Skip to Content
Merck

Utilizing mouse optic nerve crush to examine CNS remyelination.

STAR protocols (2021-11-18)
Tracey A C S Suter, Jing Wang, Huyan Meng, Zhigang He
ABSTRACT

In developing pro-myelination treatment, an important hurdle is the lack of reliable animal models for assessing de novo myelination in disease settings. We recently showed that regenerated axons in injured optic nerves fail to be myelinated, providing an animal model for this purpose. Here, we describe procedures to promote axonal regeneration, administer optic nerve crush, and assess oligodendrocyte differentiation and maturation into myelination-competent oligodendrocytes. This protocol allows for testing the efficacy of remyelination treatments in an in vivo central nervous system (CNS). For complete details on the use and execution of this protocol, please refer to Wang et al. (2020) and Bei et al. (2016).

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Myelin Associated Glycoprotein Antibody, clone 513, clone 513, Chemicon®, from mouse
Sigma-Aldrich
Anti-Olig2 Antibody, clone 211F1.1, Alexa Fluor488 Conjugate | MABN50A4, clone 211F1.1, from mouse, ALEXA FLUOR 488
Sigma-Aldrich
Anti-Aspa/Nur7 Antibody, from rabbit, purified by affinity chromatography